Study shows immunotherapy may benefit a subset of patients with penile cancer

Penile cancer is a rare disease with approximately 2,070 new cases each year in the U.S. Treatment options are limited and typically begin with platinum chemotherapy. Immune checkpoint inhibitors (ICIs) are novel therapies that are active in several cancer types but are understudied in penile cancer. Clinical trials to evaluate ICIs for penile cancer are challenging to run because the cancer is so rare.

Leave A Comment

Your email address will not be published. Required fields are marked *